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Abstract
Introduction Systemic chemotherapy is an important part of
treatment for breast cancer. We conducted the present study to
evaluate whether systemic chemotherapy could produce
microsatellite instability (MSI) in the peripheral blood
mononuclear cell fraction of breast cancer patients.
Methods We studied 119 sequential blood samples from 30
previously untreated breast cancer patients before, during and
after chemotherapy. For comparison, we also evaluated 20
women who had no relevant medical history (control group).
Results In 27 out of 30 patients we observed MSI in at least one
sample, and six patients had loss of heterozygosity. We found a
significant correlation between the number of MSI events per
sample and chemotherapy with alkylating agents (P < 0.0001).
We also observed an inverse correlation between the
percentage of cells positive for hMSH2 and the number of MSI
events per sample (P = 0.00019) and use of alkylating agents
(P = 0.019).
Conclusion We conclude that systemic chemotherapy may
induce MSI and loss of heterozygosity in peripheral blood
mononuclear cells from breast cancer patients receiving
alkylating agents, possibly mediated by a chemotherapy-
induced decrease in the expression of hMSH2. These effects
may be related to the generation of secondary leukaemia in
some patients, and may also intensify the genetic instability of
tumours and increase resistance to treatment.
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Introduction
Systemic chemotherapy is an important part of treatment
for breast cancer in both the adjuvant and palliative set-
tings. Despite the consistent improvement in overall sur-
vival afforded by systemic adjuvant chemotherapy, about
1% of patients develop secondary leukaemia and/or myel-
odysplasia, probably as a consequence of the genotoxic
effects of this type of treatment [1]. Deficiencies in the DNA
mismatch repair system leading to microsatellite instability
(MSI) may produce a syndrome of familial predisposition to
colon, endometrial and upper gastrointestinal cancers,
known as hereditary nonpolyposis colon cancer [2]. The
DNA mismatch repair system depends on the coordinated
interplay of several proteins encoded by various genes,
including hMLH1, hMSH2, hPMS1 and hPMS2 [2]. Sev-
eral groups have reported a significant association
between MSI and treatment-related secondary acute mye-
loid leukaemia (AML) and myelodysplasia [3-5]. In some
studies MSI in treatment-related secondary AML/myelod-
ysplasia cases was accompanied by hMLH1 hypermethyl-
ation [3] and MSH2 polymorphisms [6].
In order to evaluate whether systemic chemotherapy could
produce MSI in normal peripheral blood mononuclear cells
AML = acute myeloid leukaemia; LOH = loss of heterozygosity; MSI = microsatellite instability; PBMC = peripheral blood mononuclear cell; PCNA 
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(PBMCs), we analyzed PBMCs from breast cancer
patients collected before, during and after systemic
chemotherapy.
Methods
Collection and preparation of samples
This protocol was approved by our institutional review
board. We obtained blood samples from 33 patients with
histologically confirmed breast cancer after informed con-
sent had been obtained. We had only the initial sample in
three patients, and so we could not include them in the
study. We therefore studied 119 sequential blood samples
from 30 previously untreated breast cancer patients, col-
lected at 3-month intervals before, during and after receiv-
ing systemic treatment (13 adjuvant, 12 neoadjuvant and 5
palliative). Three patients initially received hormones (two
adjuvant and one palliative).
Chemotherapy combinations containing cyclophospha-
mide were classified as alkylating regimens (FAC [5-fluor-
ouracil, doxorubicin and cyclophosphamide], AC
[doxorubicin and cyclophosphamide], CMF [cyclophos-
phamide, methotrexate, and 5-fluorouracil]). We also stud-
ied PBMCs from 20 normal control women, who had no
relevant previous medical history, by immunocytochemistry.
Afterward, we collected peripheral blood from these 20
normal control women on two occasions with a 3-month
interval to evaluate MSI using the TP53Alu and PCR15.1
markers (described below).
Each sample consisted of 20 ml venous blood, from which
we separated the PBMCs by Ficoll gradient (Ficoll
Hypaque; Organon Teknica®, Durham, NC, USA), yielding
a final concentration of 1.0 × 106 cells/ml; we sent part of
the sample for cytospin for immunocytochemical studies
and part for DNA extraction. DNA was extracted from
mononuclear fraction by the use of Trizol (Invitrogen,
Carlsbad, CA, USA), in accordance with the manufac-
turer's instructions. For immunocytochemistry analysis,
assay slides were prepared (described in detail elsewhere
[7]).
Microsatellite analysis
The sequences of all primers used for six microsatellite loci
(BAT-26, BAT-40, MFD-28, MFD-41, TP53, PCR15.1,
TP53ALU) and the PCR protocols used to study each of
these markers were described previously [8]. Briefly, PCR
products were denatured and subjected to electrophoresis
in Gene Gel Clean 15/24 (Amershan Pharmacia Biotech
AB, Uppsala, Sweden) for 90 min at 600 V and 8°C, and
then silver stained using a Hoefer Automed Gel Stainer
(Amershan Pharmacia Biotech AB). MSI was defined by
the appearance of novel bands and loss of heterozygosity
(LOH) whenever disappearance of previously visualized
bands occurred, as described previously [8]. Three inde-
pendent observers analyzed the results of each gel for LOH
and MSI.
Immunocytochemistry
For immunostaining for proliferating nuclear antigen
(PCNA), hMLH1, hPMS1, hPMS2, hMSH2 and TP-53 pro-
teins, we used an avidin–biotin–peroxidase complex and
3,3'-diaminobenzidine as chromogen. All antibodies were
supplied by Santa Cruz Biotechnology (Santa Cruz, CA,
USA), and for each clone we employed the following dilu-
tions: PC-10 (anti-PCNA), 1:1000; C-20 (anti-hMLH1),
1:25; K-20 (anti-hPMS1), 1:25; C-20 (anti-hPMS2),
1:200; N-20 (anti-hMSH2), 1:200; and Pab1801 (anti-
P53), 1:400. Endogenous peroxidase activity was blocked
by incubation with H2O2 and washed in tap water. The cyt-
ospin slides were then treated with 7% skimmed milk for 60
min to block nonspecific protein binding. Each antibody
was applied separately, and cytospins were incubated for
18 hours at 3°C. After 3 washes in phosphate-buffered
saline, antigen-bound primary antibody was detected using
a standard streptavidin–biotin complex (Strep AB Com-
plex; Dako, Carpinteria, CA, USA). After brief washing,
slides were incubated with diaminobenzidine and H2O2 for
10 min and then counterstained with haematoxylin, dehy-
drated in graded alcohols and cleared in xylene. Two inde-
pendent observers scored 300 cells/slide as positive or
negative according to the presence of nuclear staining for
each of the aforementioned antibodies. Then, the results
from these two observers were averaged to obtain a per-
centage of positive cells per sample.
Statistical methods
We analyzed correlations between categorical variables
using the χ2 or Fisher's exact test. We used analysis of var-
iance to study correlations between continuous and cate-
gorical variables, and simple regression to analyze
correlations between continuous variables.
Results
We studied 30 patients with median age 52 years (range
25–80 years). Twelve patients had stage II, 13 had stage III
Table 1
Peripheral blood mononuclear cells positive for each of the 
studied markers by immunocytochemistry
Protein Percentage
PCNA 15.93 ± 4.38
hMLH1 0.25 ± 1.11
hPMS1 0.6 ± 0.99
hPMS2 0 ± 0
hMSH2 72.7 ± 20.33
TP53 0 ± 0
Values are expressed as mean ± standard deviation (%).Available online http://breast-cancer-research.com/content/7/1/R28
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and five had stage IV breast cancer. We evaluated samples
from 20 normal control women by immunocytochemistry for
PCNA, hMLH1, hPMS2, hMSH2 and TP-53 (Table 1); the
raw data for each of the included patients appear in Addi-
tional file 1.
We observed MSI in 40 out of the 119 samples collected,
and MSI was observed in 27 out of 30 patients in at least
one sample. We observed LOH at the PCR15.1 locus in six
patients. Whereas MSI was usually transient, disappearing
in the next collected sample, LOH was persistent in all sub-
sequent samples in five of the six observed cases (Fig. 1).
In order to ensure that our findings in the patients studied
were not due to chance, we s t u d i e d  2 0  n o r m a l  b l o o d
donors (women who had no relevant medical history; see
Additional file 2). In those women blood samples were col-
lected twice, with a 3-month interval between samples. We
studied both samples from each of these normal women for
MSI using TP53ALU and PCR15.1 markers. In only one
normal woman was any MSI identified (one additional band
was detected in the PCR15-1 marker after 3 months).
None of them had LOH (data not shown). Therefore, in only
one blood sample out of 40 drawn from these 20 normal
women was there any evidence of MSI, as compared with
28 out of 119 samples from the breast cancer patients
studied using the same markers (P = 0.018).
We observed a significant correlation between the number
of MSI events per sample and the use of chemotherapy (P
= 0.005), especially chemotherapy containing alkylating
agents (P < 0.0001; Fig. 2). We also observed an inverse
correlation between the number of MSI events per sample
and the percentage of cells positive for MSH2 by immuno-
cytochemistry (P = 0.00019) and especially for the MFD41
marker (P = 0.000638). The percentage of cells positive
for MSH2 by immunocytochemistry was inversely corre-
lated with the use of chemotherapy regimens containing
alkylating agents (P = 0.019). We found no significant cor-
relations between the number of MSI events or the pres-
ence of LOH and the frequency of cells positive for TP53,
hMLH1, hPMS1 and hPMS2.
In the present study, the percentage of cells positive for
PCNA, as determined by immunocytochemistry, was
directly correlated with use of radiation therapy (P = 0.046)
and with the percentage of MSH2-positive cells (P  =
0.000096), and inversely correlated with the presence of
LOH (P = 0.043), but it was not correlated with the number
of MSI events per sample.
Discussion
Systemic chemotherapy administered to breast cancer
patients induces secondary leukaemia and myelodysplasia
in about 1% [1]. In our study, in 90% of patients MSI was
noted in at least one of the samples. This finding does not
appear due to chance because only one of the sequential
blood samples drawn from 20 normal donor women exhib-
ited MSI. Furthermore, we observed a significant and direct
correlation between the number of MSI events per sample
and the use of chemotherapy, especially with regimens
containing alkylating agents. We believe that our data
reflect the genotoxic effects of chemotherapy on normal
cells because in only one normal control woman out of 20
was there evidence of MSI (after 3 months) and with only
one of the two surveyed MSI markers. Furthermore, no
LOH was observed within this cohort of normal women.
Therefore, because MSI and LOH occurred at significantly
greater frequency among patients with breast cancer, it is
unlikely that our findings could be due to normal variations
in MSI occurrence or to technical artifacts.
We also noted a significant, inverse correlation between
the number of MSI events per sample and the expression
of hMSH2 by immunocytochemistry. Because we noted
fluctuation in hMSH2 levels throughout the treatment of
several patients, it is possible that hMSH2 downregulation
occurs at the post-transcriptional level and could be related
to the use of chemotherapy based on alkylating agents.
Interestingly, Watanabe and coworkers [9] described
induction of MSI in ovarian tumours from patients studied
before and after they received cisplatin-based chemother-
apy, but in their study the cisplatin-induced MSI correlated
with a significant decrease in hMLH1 expression.
Figure 1
Loss of heterozygosity (LOH) and microsatellite instability (MSI)  occurrence Loss of heterozygosity (LOH) and microsatellite instability (MSI) 
occurrence. (a) The clinical course of one of the studied patients who 
received three cycles of neoadjuvant paclitaxel (P) followed by four 
cycles of neoadjuvant doxorubicin with cyclophosphamide (AC) before 
surgery (Sx) and radiation therapy (Rxt). Each star below the straight 
line indicates a blood sample collection (time intervals between collec-
tions are not to scale). (b) Single-strand conformation polymorphism 
(SSCP) gels for two MSI markers PCR15.1 and ALU from the patient 
represented in panel a, showing the occurrence of LOH and MSI (black 
arrows). Each lane corresponds to one of the blood samples collected 
from this patient. Note that MSI disappears whereas LOH persists.Breast Cancer Research    Vol 7 No 1    Fonseca et al.
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We believe that the transient decrease in hMSH2 expres-
sion that we noted might have predisposed to an increased
number of MSI events. In fact, Zhu and coworkers [10] also
described abnormal hMSH-2 expression in about one-third
of cases of AML, mainly in those with treatment-related sec-
ondary AML and in patients who were elderly.
PCNA is a 36 kDa nuclear protein that functions as a cofac-
tor for δ-DNA polymerase, which is regulated in a cell cycle
dependent manner. PCNA expression also increases when
cells are actively engaged in DNA repair [11]. The correla-
tion of PCNA with LOH but not with the number of MSI
events found in the present study may indicate that PCNA
may have greater expression in situations of more intense
DNA damage that tend to be long-lasting. Interestingly, our
group previously showed that PCNA over-expression was
associated with resistance to chemotherapy AML and
chronic lymphocytic leukaemia [12,13].
Conclusion
We conclude that systemic chemotherapy may induce MSI
and LOH in PBMCs from breast cancer patients receiving
chemotherapy regimens, especially chemotherapy regi-
mens containing alkylating agents. Furthermore, it is possi-
ble that these alterations are associated with a
chemotherapy-induced decrease in the expression of
hMSH2. These effects may be related to the generation of
secondary leukaemia in some patients, and may also inten-
sify the genetic instability of tumours and increase resist-
ance to treatment.
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Figure 2
Correlations between microsatellite instability (MSI) events, treatment, and hMSH2-positive cells. Significant correlations between (a) number of  MSI events and type of treatment received by patients during which samples were collected (2, alkylating chemotherapy; 3, nonalkylating chemo- therapy; 4, radiation therapy; 5, hormone therapy; and 6, off treatment), (b) percentage of hMSH2-positive cells and number of MSI events (MSI and  loss of heterozygosity [LOH]), and (c) percentage of hMSH2-positive cells and type of treatment received by patients during which samples were  collected (1, before treatment; 2, alkylating chemotherapy; 3, nonalkylating chemotherapy; 4, radiation therapy; 5, hormone therapy; 6, off treatment) Correlations between microsatellite instability (MSI) events, treatment, and hMSH2-positive cells. Significant correlations between (a) number 
of MSI events and type of treatment received by patients during which samples were collected (2, alkylating chemotherapy; 3, nonalkylating chemo-
therapy; 4, radiation therapy; 5, hormone therapy; and 6, off treatment), (b) percentage of hMSH2-positive cells and number of MSI events (MSI and 
loss of heterozygosity [LOH]), and (c) percentage of hMSH2-positive cells and type of treatment received by patients during which samples were 
collected (1, before treatment; 2, alkylating chemotherapy; 3, nonalkylating chemotherapy; 4, radiation therapy; 5, hormone therapy; 6, off treatment). 
Values are expressed as means and standard errors (for P values see text).
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The following Additional files are available online:
Additional File 1
An Excel file showing raw data for each patient studied.
See http://www.biomedcentral.com/content/
supplementary/bcr950-S1.xlsAvailable online http://breast-cancer-research.com/content/7/1/R28
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sample showed an extra band with the marker PCR15.1 
(indicated by an arrow).
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